← Back to Search

Anti-metabolites

Methotrexate For The Prevention and Treatment of Proliferative Vitreoretinopathy in Pediatric Patients (SIGHT Trial)

Phase 1
Waitlist Available
Led By Edward Wood, MD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

This trial is testing whether methotrexate can help improve outcomes for children with retinal detachment caused by a tear.

Eligible Conditions
  • Proliferative Vitreoretinopathy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Recurrence of Retinal Detachment

Side effects data

From 2015 Phase 3 trial • 139 Patients • NCT02001987
11%
Rheumatoid arthritis
11%
Rhinitis
9%
Asthenia
9%
Bronchitis
8%
Nasopharyngitis
8%
Alanine aminotransferase increased
8%
Arthralgia
8%
Headache
7%
Neutropenia
6%
Diarrhoea
5%
Back pain
5%
Hepatocellular injury
5%
Transaminases increased
5%
Insomnia
5%
Abdominal pain
4%
Urinary tract infection
3%
Ear infection
3%
Injection site erythema
3%
Pruritus
2%
Nausea
2%
Hypertension
1%
Gastric volvulus
1%
Angioedema
1%
Gastric ulcer
1%
Intestinal ischaemia
1%
Pulmonary embolism
1%
Deep vein thrombosis
1%
Hypertensive crisis
1%
Iron deficiency anaemia
1%
Cataract
1%
Cervical dysplasia
1%
Disseminated tuberculosis
1%
Septic shock
1%
Meningitis tuberculous
1%
Fall
100%
80%
60%
40%
20%
0%
Study treatment Arm
TCZ COMBO - All Participants
TCZ MONO - All Participants
TCZ - All Participants

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: TreatmentExperimental Treatment1 Intervention
Methotrexate treatment
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Methotrexate
FDA approved

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,487 Previous Clinical Trials
17,517,529 Total Patients Enrolled
Edward Wood, MDPrincipal InvestigatorStanford University
Quan Dong Nguyen, MD, MScPrincipal InvestigatorStanford University
1 Previous Clinical Trials
Ahmad Al-Moujahed, MD, PhD, MPHPrincipal InvestigatorStanford University
Hashem Ghoraba, MDPrincipal InvestigatorStanford University
Darius Moshfeghi, MDPrincipal InvestigatorStanford University
1 Previous Clinical Trials
1 Total Patients Enrolled
~0 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top